Activator of thyroid and retinoid receptor increases sorafenib resistance in hepatocellular carcinoma by facilitating the Warburg effect

Sorafenib resistance is a major challenge in the therapy for advanced hepatocellular carcinoma (HCC). However, the underlying molecular mechanisms of HCC resistance to sorafenib remain unclear. Activator of thyroid and retinoid receptor (ACTR, also known as SRC‐3), overexpressed in HCC patients, pla...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer Sci
Autors principals: Ma, Luyuan, Liu, Wenpeng, Xu, An, Ji, Quanbo, Ma, Yongfu, Tai, Yanhong, Wang, Yadong, Shen, Chuan, Liu, Ying, Wang, Tao, Han, Juqiang, Zhao, Caiyan
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2020
Matèries:
Original Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7293092/
https://ncbi.nlm.nih.gov/pubmed/32279388
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.14412
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars